Introduction/Background Ovarian cancer is the most fatal gynecologic malignancy. Low-grade type represents only 2–5% of ovarian carcinoma. Its clinical characteristics, growth pattern, and response to treatment are distinct from high-grade serous ovarian carcinoma. In this study, we retrospectively evaluated the clinical features, prognostic factors, and survival of patients diagnosed with low-grade serous ovarian cancer from a tertiary centre.

Methodology This is a retrospective study where all patients diagnosed with low-grade ovarian cancer who presented to a tertiary cancer center were included from July 2015 to August 2021.

Results 42 patients with low-grade ovarian serous carcinoma were enrolled. The mean age of the patients was 50.17±10.91 years, while the mean BMI was 32.96±6.02 kg/m2. Primary optimal debulking was performed in 18 patients, while interval cytoreduction was done in 17 patients. Suboptimal debulking was performed in 5 patients. Neoadjuvant chemotherapy was administered in 19 patients (45.2%). The median overall survival of LGSOC patients was 95.58(73.37–117.79) months while the median PFS was 56.54(38.15–74.94) months.

Conclusion Surgery is still the cornerstone of the management of low-grade serous ovarian cancer. However, Neoadjuvant chemotherapy could be a predictor of progression-free survival in low-grade serous ovarian carcinoma patients.

Disclosures Surgery is still the cornerstone of the management of low-grade serous ovarian cancer. However, Neoadjuvant chemotherapy could be a predictor of progression-free survival in low-grade serous ovarian carcinoma patients.